Skip to main content
. 2015 Apr 30;33(26):2955–2962. doi: 10.1016/j.vaccine.2015.04.071

Fig. 2.

Fig. 2

A schematic representation depicting the use of pseudotyped virus as antigen within a neutralisation assay set up.